Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation.

Abstract:

:Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard to morbidity associated with OM. Clinical information was gathered on 167 patients undergoing HSCT and divided according to the presence (n = 91) or absence (n = 76) of laser therapy and oral care. Cost analysis included daily hospital fees, parenteral nutrition (PN) and prescription of opioids. It was observed that the group without laser therapy (group II) showed a higher frequency of severe degrees of OM (relative risk = 16.8, 95% confidence interval -5.8 to 48.9, p < 0.001), with a significant association between this severity and the use of PN (p = 0.001), prescription of opioids (p < 0.001), pain in the oral cavity (p = 0.003) and fever > 37.8°C (p = 0.005). Hospitalization costs in this group were up to 30% higher. The introduction of oral care by a multidisciplinary staff including laser therapy helps reduce morbidity resulting from OM and, consequently, helps minimize hospitalization costs associated with HSCT, even considering therapy costs.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Bezinelli LM,de Paula Eduardo F,da Graça Lopes RM,Biazevic MG,de Paula Eduardo C,Correa L,Hamerschlak N,Michel-Crosato E

doi

10.1002/hon.2050

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

31-9

issue

1

eissn

0278-0232

issn

1099-1069

journal_volume

32

pub_type

杂志文章
  • Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.

    abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64

    authors: Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

    更新日期:1999-12-01 00:00:00

  • Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort.

    abstract::Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2092

    authors: Goldschmidt N,Cohen SB,Gatt ME,Safrai M,Rund D

    更新日期:2014-06-01 00:00:00

  • Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.

    abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1002/hon.2152

    authors: Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

    更新日期:2015-09-01 00:00:00

  • Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

    abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2515

    authors: Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

    更新日期:2018-10-01 00:00:00

  • Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

    abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2652

    authors: Della Starza I,Cavalli M,De Novi LA,Genuardi E,Mantoan B,Drandi D,Barbero D,Ciabatti E,Grassi S,Gazzola A,Mannu C,Agostinelli C,Piccaluga PP,Bomben R,Degan M,Gattei V,Guarini A,Foà R,Galimberti S,Ladetto M,Ferrero

    更新日期:2019-10-01 00:00:00

  • Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

    abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120104

    authors: Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

    更新日期:1994-01-01 00:00:00

  • Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.

    abstract::There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA brea...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1020

    authors: Golla RM,Li M,Shen Y,Ji M,Yan Y,Fu K,Greiner TC,McKeithan TW,Chan WC

    更新日期:2012-12-01 00:00:00

  • Acute myeloid leukemia in elderly adults.

    abstract::One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080103

    authors: Tucker J,Thomas AE,Gregory WM,Ganesan TS,Malik ST,Amess JA,Lim J,Willis L,Rohatiner AZ,Lister TA

    更新日期:1990-01-01 00:00:00

  • Relationship between myeloblasts and cluster-forming cells in acute non-lymphocytic leukemia.

    abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900020210

    authors: Gustavsson A,Olofsson T,Olsson I

    更新日期:1984-04-01 00:00:00

  • Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin

    abstract::Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2729

    authors: Schütz NP,Ochoa P,Duarte P,Remaggi G,Yantorno S,Corzo A,Zabaljauregui S,Shanley C,Lopresti S,Orlando S,Verri V,Quiroga L,García CA,Fernández V,Fantl D

    更新日期:2020-08-01 00:00:00

  • Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

    abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2378

    authors: Sorigue M,Mercadal S,Alonso S,Fernández-Álvarez R,García O,Moreno M,Pomares H,Alcoceba M,González-García E,Motlló C,González-Barca E,Martin A,Sureda A,Caballero D,Ribera JM,Sancho JM

    更新日期:2017-12-01 00:00:00

  • No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.

    abstract::This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2091

    authors: Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

    更新日期:2014-06-01 00:00:00

  • First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.

    abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.822

    authors: Andrikovics H,Nahajevszky S,Szilvási A,Bors A,Adám E,Kozma A,Kajtár B,Barta A,Poros A,Tordai A

    更新日期:2007-09-01 00:00:00

  • Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.

    abstract::Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2178

    authors: Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

    更新日期:2016-03-01 00:00:00

  • Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.

    abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2427

    authors: Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

    更新日期:2018-02-01 00:00:00

  • Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells.

    abstract::To clarify the origin of Hodgkin (H) and Sternberg-Reed (SR) cells, frozen sections of lymph nodes from 30 patients with Hodgkin's disease were immunostained with a large panel of monoclonal antibodies reactive with cells of lymphoid tissue and granulopoiesis. The results showed that: (a) H and SR cells are devoid of ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900010105

    authors: Stein H,Gerdes J,Schwab U,Lemke H,Diehl V,Mason DY,Bartels H,Ziegler A

    更新日期:1983-01-01 00:00:00

  • Residual mediastinal widening following therapy in Hodgkin's disease.

    abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080303

    authors: Orlandi E,Lazzarino M,Brusamolino E,Caldera D,Morra E,Dore R,Di Giulio G,Bernasconi C

    更新日期:1990-05-01 00:00:00

  • Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process.

    abstract::Some patients with cerebriform T-cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transfo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080406

    authors: Greer JP,Salhany KE,Cousar JB,Fields JP,King LE,Graber SE,Flexner JM,Stein RS,Collins RD

    更新日期:1990-07-01 00:00:00

  • Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables.

    abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2520

    authors: Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li J

    更新日期:2018-10-01 00:00:00

  • Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.

    abstract::Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2809

    authors: Miura K,Tsujimura H,Masaki Y,Iino M,Takizawa J,Maeda Y,Yamamoto K,Tamura S,Yoshida A,Yagi H,Yoshida I,Kitazume K,Masunari T,Choi I,Kakinoki Y,Suzuki R,Yoshino T,Nakamura S,Hatta Y,Yoshida T,Kanno M

    更新日期:2020-09-25 00:00:00

  • Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9.

    abstract::The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030306

    authors: Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

    更新日期:1985-07-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome.

    abstract::Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2162

    authors: Shiratori S,Fujimoto K,Nishimura M,Hatanaka KC,Kosugi-Kanaya M,Okada K,Sugita J,Shigematsu A,Hashimoto D,Endo T,Kondo T,Abe R,Hashino S,Matsuno Y,Shimizu H,Teshima T

    更新日期:2016-03-01 00:00:00

  • Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines.

    abstract::Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900040303

    authors: Kontoghiorghes GJ,Piga A,Hoffbrand AV

    更新日期:1986-07-01 00:00:00

  • Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis.

    abstract::Previous studies have shown that the incidence of non-Hodgkin's lymphoma (NHL) has increased in many parts of the world in recent decades. Using data obtained from the Canadian Cancer Registry, the present study examined time trends in NHL incidence in Canada between 1970 and 1996 and the effects of age, period of dia...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.703

    authors: Liu S,Semenciw R,Mao Y

    更新日期:2003-06-01 00:00:00

  • A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract::Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2141

    authors: Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

    更新日期:2015-06-01 00:00:00

  • In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.

    abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2724

    authors: Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

    更新日期:2020-10-01 00:00:00

  • Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

    abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2635

    authors: Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

    更新日期:2019-08-01 00:00:00

  • Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).

    abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080205

    authors: Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

    更新日期:1990-03-01 00:00:00

  • A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.

    abstract::These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2454

    authors: Kiesewetter B,Neuper O,Mayerhoefer ME,Dolak W,Lukas J,Simonitsch-Klupp I,Raderer M

    更新日期:2018-02-01 00:00:00

  • The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

    abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.780

    authors: Abidi MH,Kozlowski JR,Ibrahim RB,Peres E

    更新日期:2006-09-01 00:00:00